SAR445877

Phase 2Small molecule

Sanofi

SAR445877 is one of 110 small molecule programs targeting Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

109

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

SAR445877Recruiting

Non-Small Cell Lung CancerRecruiting

Gastric CancerRecruiting

Solid TumorPreclinical

Recruiting

SAR445877Phase 1

Recruiting

Non-Small Cell Lung CancerPhase 2

Recruiting

Gastric CancerPhase 2

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Furmonertinib

AAllist Pharmaceuticals, Inc.

Phase 3

6 2

Albumin Paclitaxel

CChipscreen Biosciences, Ltd.

Phase 3

3 3

TY-9591

TTYK Medicines, Inc

Phase 3

2 4

SAR445877

Sanofi

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Solid Tumor

NCT05584670

Q3 2028

Phase 2Recruiting

Gastric Cancer

NCT07692204

Q1 2030

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT07133425

Q4 2032

Phase 1Recruiting

SAR445877

NCT07500298

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07133425·29 enrolled

SAR4458771 trial

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07500298·41 enrolled

Gastric Cancer1 trial

A Phase 2, Open-label, Dose Optimization/Expansion Study of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Gastric or Gastroesophageal Junction Cancer

Recruiting· Sanofi logo

Sanofi·Phase 2·NCT07692204·30 enrolled

Solid Tumor1 trial

A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors

Recruiting· Sanofi logo

Sanofi·Preclinical·NCT05584670·542 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SAR445877. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR445877 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR445877. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

SAR445877

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2028

Q1 2030

Q4 2032

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

SAR4458771 trial

Gastric Cancer1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News